Scan a molecule portfolio for lanes with HHI above the structural concentration threshold. Find implicit single-sourcing exposure before it disrupts supply.
Sitagliptin exports from India sit at HHI 8044 into the US, 7820 into Saudi Arabia, and 6751 into Turkey with five to seven active exporters carrying 97 to 99% of lane value. The medium-sized lanes look diversified on a headcount basis but the top-3 share tells the structural story. Every lane in this list crosses the DOJ near-monopoly threshold; the dual-source workflow is the next step.
| # | Lane | Origin · Dest | Lane HHI | Exporters | Top-3 share |
|---|---|---|---|---|---|
| 1 | Sitagliptin · IN → SA | Saudi Arabia | 5 active exporters | $9.97M | NAI |
| 2 | Sitagliptin · IN → US | United States | 7 active exporters | $3.38M | VAI |
| 3 | Sitagliptin · IN → TR | Turkey | 12 active exporters | $11.02M | NAI |
| 4 | Linagliptin · IN → SA | Saudi Arabia | 5 active exporters | $5.97M | NAI |
| 5 | Linagliptin · IN → TR | Turkey | 10 active exporters | $2.39M | NAI |
A single molecule or a portfolio. Sitagliptin, linagliptin, vildagliptin in one query if you source the DPP-4 inhibitor class.
Lane competitiveness joined to trade flows. Any lane above HHI 6000 surfaces with the exporter count, top-3 share, and 12-month value.
Citation-anchored brief, ranked by lane value. One click hands each concentrated lane into the dual-source candidate workflow.
A lane with two contracts looks safe on paper. If those two suppliers carry 90% of the lane, you are still structurally single-sourced.
Run across 50 molecules in one query. The top concentrated lanes ranked by combined exposure surface as a single list.
HHI above 6000 is the default near-monopoly threshold. Tune to 4000 if you are a conservative procurement function. Alerts fire on every refresh.
A lane with HHI 8000 and 12 exporters has a different playbook than HHI 8000 and 5 exporters. Both numbers matter.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Lanes in the latest blockbuster pool with HHI above 6000 and at least $2M in 2024 trade · active exporter counts shown.
The portfolio lane scan is the structural risk view across your sourced molecules. PharmaDB surfaces every lane in the basket above the configurable HHI threshold, ranks by combined value at risk, and hands the top exposures into the dual-source workflow. The view is lane_competitiveness; the join is to molecule_country_flow.
PharmaDB's default threshold is the US DOJ near-monopoly line. 4000 is the structurally-concentrated threshold and surfaces a wider list. Both are tunable in the query; the default returns the lanes where action is non-optional.
Pass a molecule list, a class (DPP-4 inhibitors, SGLT-2 inhibitors, BTK inhibitors), or a destination market. The AI agent filters before running the lane scan, so the result is portfolio-relevant rather than a global league table.
It surfaces with a structural single-source flag rather than an HHI value. A two-exporter lane is mathematically not measurable on HHI but is operationally the highest-risk case.
Lane Concentration Risk answers one lane at a time. High-Concentration Lane Detection is the portfolio scan. Same underlying view, different orchestration.
Yes. The methodology is identical for API, FDF, biosimilars, and intermediates. FDF lanes add a regulatory check for the local marketing authorisation, surfaced as a separate column.
Trade aggregates refresh weekly. Lane competitiveness recomputes on every refresh. The catalog row carries the last-computed timestamp surfaced on every result page.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.